Showing 3511-3520 of 5621 results for "".
- Vabysmo Prefilled Syringe (PFS) Approved in the EUhttps://modernod.com/news/vabysmo-prefilled-syringe-pfs-approved-in-the-eu-for-three-retinal-conditions/2482582/The European Medicines Agency (EMA) has approved Roche's Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion
- Viridian Announces Topline Results from Veligrotug Phase 3 Trial in Patients with Chronic TEDhttps://modernod.com/news/viridian-announces-positive-topline-results-from-veligrotug-phase-3-trial-in-patients-with-chronic-thyroid-eye-disease/2482580/Viridian Therapeutics announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED). “We are extremely
- CellViva Appoints Three Ophthalmology Leaders to Board of Directorshttps://modernod.com/news/cellviva-appoints-three-ophthalmology-leaders-to-board-of-directors/2482577/CellViva, a biopharmaceutical company developing anti-vascular endothelial growth factor—anti-VEGF—therapy for pterygium, announced the appointment of three leaders in ophthalmology to its Board of Directors. According to CellViva, the new directors are: Ad
- Bausch + Lomb Acquires Elios Vision to Bolster Glaucoma Surgical Portfoliohttps://modernod.com/news/bausch-lomb-acquires-elios-vision-to-bolster-glaucoma-surgical-portfolio/2482575/Bausch + Lomb announced that an affiliate has acquired Elios Vision, developer of the ELIOS procedure, a minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. Financial terms of the deal were not disclosed. According to B+
- Iantrek Publishes 12-Month Results for its Bio-Interventional Uveoscleral Outflow Technologyhttps://modernod.com/news/iantrek-announces-publication-highlighting-12-month-results-for-its-bio-interventional-uveoscleral-outflow-technology/2482574/Iantrek has announced 1-year results for the first 100 eyes enrolled in the CREST Registry, a real-world, prospective, observational study evaluating bio-interventional procedures in patients with open-angle glaucoma (OAG). The findings,
- UC Irvine Scientists Find DNA Damage is Key Factor in AMDhttps://modernod.com/news/uc-irvine-scientists-find-dna-damage-is-key-factor-in-amd/2482569/Accumulated DNA damage in the retina is a key contributor to age-related macular degeneration (AMD) and that targeting specific retinal cell types may lead to treatments that slow or stop progression, according to a research team co-led by the University of California, Irvine. The
- Outlook Therapeutics Receives NICE Recommendation of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-receives-nice-recommendation-for-lytenava-as-a-treatment-for-wet-amd/2482567/The UK’s National Institute for Health and Care Excellence (NICE) has recommended Lytenava (bevacizumab gamma) as an option for the treatment of wet AMD in adults. This marks the first positive reimbursement decision for Lytenava worldwide and supports its commercializat
- Nicox Announces First Commercial Sale of Zerviate in China by Partner Ocumensionhttps://modernod.com/news/nicox-announces-first-commercial-sale-of-zerviate-in-china-by-partner-ocumension/2482566/Nicox announced the first commercial sale of Zerviate (cetirizine ophthalmic solution), 0.24% in China by its exclusive Chinese partner Ocumension yesterday – a significant milestone in their longstanding collaboration since 2018. Zerviate is indicated for ocular itchin
- Galimedix Begins Phase 1 Clinical Trial of Oral GAL-101 for Neuroprotective Treatmenthttps://modernod.com/news/galimedix-therapeutics-begins-phase-1-clinical-trial-of-oral-gal-101-for-neuroprotective-treatment/2482565/Galimedix Therapeutics announced the first volunteers have been dosed in the company’s phase 1 study of oral GAL-101, an amyloid beta (Aβ) aggregation modulator. This trial is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses
- Ophthalmic Industry Veteran Scott Hunter Passes Awayhttps://modernod.com/news/ophthalmic-industry-veteran-scott-hunter-passes-away/2482564/Longtime ophthalmic industry leader Scott Hunter passed away on December 3, Neurotech announced. Mr. Hunter was the Chief Commercial Officer of Neurotech, a position he held since January 2023. “The entire Neurotech family mourns this loss. On behalf of the Board of Directors, man